{"publication_id":"b9fecb64-f90f-46c3-bb5b-4b0f9e842bc6","traces":[{"claim_id":"claim_1","claim":"The cited direct receipts support a bounded working claim: 69%-79% of participants achieved ≥10% weight loss with semaglutide 2.4 mg (vs. 12%-27% with placebo); More participants achieved weight loss ≥5% from baseline at week 104 with semaglutide (77.1%) versus placebo (34.4%; P<0.0001).","candidate_sources":[{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":null},{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis","doi":"10.15605/jafes.037.02.14","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null}]},{"claim_id":"claim_2","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":null},{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis","doi":"10.15605/jafes.037.02.14","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null}]},{"claim_id":"claim_3","claim":"_Evidence-map boundary: cited receipts are separate evidence streams unless an integrated analysis is explicitly stated; this memo maps a testable contrast, not a pooled meta-analysis or settled conclusion._","candidate_sources":[{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":null},{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis","doi":"10.15605/jafes.037.02.14","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null}]},{"claim_id":"claim_4","claim":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?","candidate_sources":[{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":null},{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis","doi":"10.15605/jafes.037.02.14","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null}]},{"claim_id":"claim_5","claim":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._","candidate_sources":[{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":null},{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis","doi":"10.15605/jafes.037.02.14","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null}]},{"claim_id":"claim_6","claim":"_Interpretation boundary: this is a hypothesis-generating alpha map, not confirmatory evidence or a settled conclusion. The heterogeneity matters because it routes the next test to the specific population, endpoint, comparator, and time window that can replicate, rather than letting a broad topic-level effect claim leak across mismatched receipts._","candidate_sources":[{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":null},{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis","doi":"10.15605/jafes.037.02.14","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null}]}]}